HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NVNO
enVVeno Medical Corporation
There isn't enough reported data to score NVNO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NVNO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NVNO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NVNO PE Valuation
NVNO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NVNO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NVNO's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NVNO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$23.32 | +$14.48 |
| Q2 2026 | -$25.08 | +$16.92 |
| Q1 2026 | -$31.26 | +$10.04 |
| Q4 2025 | -$33.07 | +$11.38 |
| Q3 2025 | -$37.80 | +$7.00 |
| Q2 2025 | -$42.00 | +$6.30 |
| Q1 2025 | -$41.30 | +$16.45 |
| Q4 2024 | -$44.45 | +$22.40 |
NVNO has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NVNO Quarterly Revenue
NVNO and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NVNO has the stronger cash trend. Its trailing FCF is down 11% versus its history, compared with HIMS at down 84%.
NVNO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.4M | +$1.7M |
| Q3 2025 | -$4.4M | -$107K |
| Q4 2024 | -$5.1M | -$132K |
| Q3 2024 | -$4.3M | -$69K |
| Q2 2024 | -$3.9M | +$662K |
| Q1 2024 | -$3.6M | +$1.6M |
| Q4 2023 | -$5M | -$1.1M |
| Q3 2023 | -$4.2M | +$281K |
NVNO has burned cash in almost every quarter: −$16M over the past year, against −$17M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NVNO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NVNO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.4% | +23K shares |
| 1 year | +21% | +118K shares |
| 3 years | +116% | +373K shares |
| 5 years | +185% | +451K shares |
| Available history | +3753% | +676K shares |
NVNO has 694,000 diluted shares, up 21% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NVNO Net Leverage
NVNO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NVNO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.5 | Neutral |
| Stochastic | 5.4 | Oversold |
NVNO's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NVNO PE vs Healthcare Sector
NVNO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NVNO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.46 | 12% below |
| 20 week MA | $9.37 | 30% below |
| 50 week MA | $10.5 | 37% below |
| 100 week MA | $53.1 | 88% below |
| 200 week MA | $108.7 | 94% below |
NVNO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NVNO on returns for 2026, with the stronger performance.
NVNO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $426.3 | $281.8 | -34% |
| 2021 | $281.8 | $241.2 | -14% |
| 2022 | $241.2 | $161.4 | -33% |
| 2023 | $161.4 | $182.7 | +13% |
| 2024 | $182.7 | $112.0 | -39% |
| 2025 | $112.0 | $12.8 | -89% |
| 2026 YTD | $12.8 | $6.58 | -49% |
NVNO has finished lower in five of the last six years. It's down 49% so far in 2026.